Comparison of antiplatelet therapy with PLAVIX or domestic Clopidogrel Bisulfate for patients undergoing coronary stenting:a randomized controlled trial
- VernacularTitle:冠状动脉支架术后进口氯吡格雷(波立维)与国产氯吡格雷(泰嘉)抗血小板治疗的对照研究
- Author:
Chunshan LU
;
Zhiqiang ZHOU
;
Jinghua LIU
- Publication Type:Journal Article
- Keywords:
Blood platelets;
Aspirin;
PLAVIX;
Clopidogrel bisulfate;
Angioplasty,transluminal,percutaneons coronary
- From:
Chinese Journal of Interventional Cardiology
1993;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
0.05),as well as in the composite of MACCE(0.47% vs 1.14%) between the two groups.Also,no significant difference existed in the rate of target vessel revascularization(3.48% vs 3.28%,P=0.958),occlusion of lower extremity artery(0.67% vs 0.82%,P=0.857) and hemorrhagic events(0.67% vs 0.82%,P=0.613) between the two groups.Kaplan-Meier survival analysis showed the cumulative hazard rate for the MACCE was similar(P=0.521).There were 5 and 4 CR patients in the Plavix group and the clopidogrel bisulfate group,respectively.Dose enlargement in addition to dual antiplatelet therapy decreased significantly the PAR of CR patients in both groups(78.2%?11.9%,76.2%?10.5%,vs 80.8%?13.2%,81.8%?12.2%,P
